GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
A large retrospective cohort study found that GLP-1 receptor agonist use was associated with significantly lower 5-year rates of colorectal cancer among patients with inflammatory bowel disease (IBD). The research was highlighted in a media briefing ahead of the 2026 ASCO Breakthrough Meeting,...
Intraoperative Margin Assessment With Specimen PET/CT Imaging in Early Breast Cancer
In a European trial (BrIMA) reported in JAMA Surgery, Göker et al found that specimen PET/CT imaging was associated with improved detection of positive margins in surgery for early breast cancer.
Study Details
The study recruited patients from six European breast centers between June 2022 and March ...
No Survival Benefit From Chemoradiotherapy After D2 Gastrectomy in Gastric Cancer
The addition of radiotherapy to the S-1 plus oxaliplatin (SOX) chemotherapy regimen did not improve disease-free or overall survival in patients with pathologic T4 and/or node-positive gastric adenocarcinoma who underwent D2 gastrectomy (ie, R0 resection with D2 lymphadenectomy), based on a phase...
All-Oral Combination of Revumenib, Decitabine/Cedazuridine, and Venetoclax for Relapsed or Refractory AML
In a single-center phase I to II trial (SAVE) reported in the Journal of Clinical Oncology, Issa et al found that the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax was highly active in patients with relapsed or refractory acute myeloid leukemia (AML).
Revumenib is an...
Investigators Identify Resistance Mechanism to Tagraxofusp Among Patients With BPDCN
Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia called blastic plasmacytoid dendritic cell neoplasm (BPDCN) may eventually develop resistance to tagraxofusp-ezrs, the first U.S. Food and Drug Administration–approved...
Inotuzumab Ozogamicin Induces Long-Term Survival in B-Cell ALL
Inotuzumab ozogamicin was able to eliminate residual disease among adult patients with B-cell acute lymphoblastic leukemia (ALL), leading to improved long-term overall survival outcomes, according to findings from a single-center phase II trial published in Blood Cancer Journal.
“Our results show...
Ten-Year Follow-up Shows Durable Remissions After CAR T-Cell Therapy for B-Cell Lymphoma
In the long-term follow-up to a phase II study published in The New England Journal of Medicine, Ruella et al found that a single infusion of the CD19-directed chimeric antigen receptor (CAR) T-cell therapy CTL019 (now called tisagenlecleucel) produced decade-long remissions in a subset of patients ...
Two-Pronged Reminders Result in Timely Conversations Around Priorities of Cancer Care
Small, targeted reminders for both clinicians and patients to have serious illness conversations led to a significant increase in the number of conversations recorded, allowing for oncologists to better honor patients' goals and wishes for their cancer care, according to findings of a randomized...
Zenocutuzumab Shows Durable Antitumor Activity in NRG1-Positive Cholangiocarcinoma
Zenocutuzumab induced clinically meaningful antitumor activity and showed a favorable safety profile in patients with advanced NRG1-positive cholangiocarcinoma, according to findings from the phase II eNRGy trial published in the Journal of Clinical Oncology.
“Second-line chemotherapy is only...
Disparities in Cancer Screening Persist Among Sexual Orientation and Gender Identity Minority Populations
New research has uncovered persistent disparities in preventive cancer care across different sexual orientation and gender identity (SOGI) minority populations. The study—published by Arena et al in the journal Cancer—found particular concern for cervical and breast cancer screening.
To assess...
Early Research Explores How Fatty Liver Disease May Affect Liver Metastasis Among Patients With Colorectal Cancer
Researchers have uncovered how fatty liver disease can fuel the most aggressive form of metastatic colorectal cancer. The findings, published by Peng-Winkler et al in Nature, not only explain why some patients face poorer outcomes but also highlight how metabolic conditions such as fatty liver...
Impact of Treatment Delays in Early-Onset Colorectal Cancer
In a retrospective, population-based, cross-sectional study reported in JAMA Oncology, Heslin et al found that treatment delay in early-onset colorectal cancer was associated with poorer overall survival.
Study Details
The study used Texas Cancer Registry data from patients diagnosed with...
Preclinical Research Shows IFN-γ May Attenuate Neutrophil Response to Cancer Immunotherapy
Researchers have discovered that the type II interferon, interferon-γ, may impact how neutrophils react to immunotherapy, either supporting or blocking the treatment for patients with cancer, according to study findings published in Immunity.
Study Methods and Key Findings
Researchers analyzed...
AI-Powered Tumor Microenvironment Analysis May Predict Immunotherapy Response in Patients With Rare Cancers
Analysis of the tumor microenvironment before and during treatment with the help of artificial intelligence (AI) may aid in predicting response to pembrolizumab in patients with rare cancers, according to findings of a study published in the Journal for ImmunoTherapy of Cancer.
“AI-based...
Performance of Lung Cancer Risk Prediction Models Across Racial and Ethnic Groups in the United States
A new study led by scientists from the International Agency for Research on Cancer (IARC) compared the performance of lung cancer risk prediction models against the criteria currently used to determine eligibility for lung cancer screening in the United States. Reseatchers found that all the...
Study Uncovers How Obesity Influences Molecular Pathways in Breast Cancer Progression
A novel study has found that obesity is associated with a distinct molecular program driving the transition from early-stage, premalignant breast lesions to invasive breast cancer. Rather than simply showing increased activation of classical invasive pathways, tumors from patients with obesity...
Study Clarifies HPV-Related Cancer Risk in Immunosuppressed Populations
As reported in JAMA Network Open by Meglic et al, a Swedish nested case-control study of immunosuppressed populations found that both people with human immunodeficiency virus (HIV) and solid organ transplant recipients had increased odds of human papillomavirus (HPV)–related cancers, although the...
Second Primary Malignancies After T-Cell–Engaging Bispecific Antibody Therapy
In a meta-analysis reported in JAMA Oncology, Tomasik et al found that second primary malignant neoplasms were a “clinically relevant complication” of treatment with T-cell–engaging bispecific antibodies (BsAbs) in patients with non-Hodgkin lymphoma or multiple myeloma.
Study Details
The...
Real-World Heart and Lung Radiation Doses From NHS Breast Radiotherapy Plans
In a study reported in The Lancet Oncology, Kirby et al identified real-world heart and lung radiation doses associated with English National Health Service (NHS) radiotherapy treatment plans in breast radiotherapy practices.
Study Details
The study involved data from 26,236 eligible patients...
Previously Untreated Advanced NSCLC With High PD-L1 Expression: PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy?
In a meta-analysis reported in JAMA Oncology, Di Federico et al found that the addition of first-line platinum-based chemotherapy to PD-1/-L1 inhibition was associated with improved outcomes in patients with advanced non–small cell lung cancer (NSCLC) with high PD-L1 expression.
Study Details
The ...
Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative
At a pivotal moment for pancreatic cancer, Break Through Cancer and the Lustgarten Foundation, with support from the Cinelli Family Foundation, has announced a $16 million investment in the Conquering KRAS for Patients with Pancreatic Cancer TeamLab. Spanning six world-class cancer research...
AACR Statement and Call to Action Concerning OMB Proposal
On June 30, the American Association for Cancer Research (AACR) issued the following statement:
The American Association for Cancer Research (AACR) is deeply concerned that the recent action of the White House Office of Management and Budget (OMB) to propose a new set of regulations on how federal ...
Breast Cancer: Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease
On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved palbociclib (Ibrance) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor (HR)-positive, HER2-positive locally advanced or...
Single-Fraction SBRT in Localized Prostate Cancer
In a phase I/II trial reported in JAMA Oncology, Zilli et al found that single-fraction high-dose stereotactic body radiotherapy (SBRT) was associated with a high biochemical relapse–free survival rate in patients with localized prostate cancer.
Study Details
In the trial, 43 patients with...
Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy
Tile-based radiation therapy (TBRT) implanted at the time of resection outperformed standard postoperative stereotactic radiation therapy (SRT) in the phase III Radiation One and Done Study (ROADS), improving surgical bed control and overall survival while maintaining a comparable safety profile,...
FDA Approves Immunotherapy to Reduce Chronic GVHD in Patients Undergoing Stem Cell Transplant
On June 30, the U.S. Food and Drug Administration (FDA) approved allogeneic regulatory T-cell–based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative...
Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma
As reported in The Lancet Oncology by Siva et al, 5-year findings in a pooled analysis of the FASTRACK and FASTRACK II trials support evidence of maintained disease control with ultra-hypofractionated stereotactic ablative body radiotherapy (SABR) in patients with primary renal cell carcinoma...
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of adults with PTEN-deficient metastatic androgen pathway modulation–naive or –sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic...
ASCO Remembers Karnofsky Award Recipient Maura L. Gillison, MD, PhD, Pioneer in HPV-Associated Cancers
Reprinted with permission from ASCO Connection, June 26, 2026.
ASCO joins the oncology community in mourning the loss of Maura L. Gillison, MD, PhD. As a medical oncologist specializing in thoracic/head and neck cancers, and as a molecular epidemiologist, Dr. Gillison definitively characterized...
Novel Risk Score Stratifies Major Bleeding Risks in Patients With VTE on DOACs
A novel bleeding risk score provides clinically relevant stratification for major bleeding risk in patients with cancer-associated venous thromboembolism (VTE) who received direct oral anticoagulant (DOAC) therapy, according to findings published in JACC: CardioOncology.
“The ONCO-DOAC BLEED...
Long-Term Outcomes With SABR in Primary Kidney Cancer
As reported in The Lancet Oncology by Siva et al, long-term outcomes of an Australian-Dutch phase II study (TROG 15.03 FASTRACK II) support the safety and local disease control seen with stereotactic ablative body radiotherapy (SABR) in patients with primary kidney cancer who did not undergo...
MRI-Guided Radiotherapy in High-Grade Glioma
In a single-center Canadian phase II trial (UNITED) reported in The Lancet Oncology, Detsky et al found that magnetic resonance imaging (MRI)-guided adaptation of radiotherapy allowed margin de-escalation and resulted in a low rate of marginal failure in patients with high-grade glioma.
Study...
I Miss My Life
Mr. A was a young professional who walked into my outpatient clinic one morning with his mother by his side. He wore a warm smile, yet there was a quiet heaviness beneath it.
A few months earlier, he had been diagnosed with a malignant brain tumor and had undergone primary treatment. He was now...
AACR Cancer Disparities Progress Report: Mortality Rates Improve, But Care Inequities Persist
The American Association for Cancer Research (AACR) released its Cancer Disparities Progress Report 2026 on June 24. The report features the unprecedented progress being made against cancer, including the ongoing decline in cancer death rates, which have decreased by 35% since 1991, translating to...
Fertility Preservation Access Remains ‘Limited and Unequal’ for Many Girls and Young Women With Cancer
A new Columbia University School of Nursing systematic review published by Algave et al in the journal Cancer reveals access to fertility preservation care remains limited and unequal for girls and young women with cancer.
Each year, more than 85,000 adolescents and young adults (AYAs)—individuals ...
Adverse Events With CD3-Based T-Cell–Engaging Bispecific Antibody Treatment in Cancer
In a meta-analysis reported in The Lancet Oncology, Zhu et al identified treatment-related adverse events associated with the use of CD3-based T-cell–engaging bispecific antibodies in patients with hematologic or solid cancers.
Study Details
The analysis included studies of CD3-based...
Survey Results Show Patients Prefer Learning of a Diagnosis From Their Doctor Rather Than a Health Portal
Most patients who receive a cancer diagnosis still prefer to learn of the diagnosis from their doctors rather than from reports uploaded to their online health portal, according to findings of a survey conducted at the University of Texas Southwestern Medical Center. Findings were published as a...
Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer
Existing agents such as statins and beta-blockers showed cardioprotective properties in select subgroups, but more treatments are needed to protect against heart failure in patients receiving treatment for cancer, according to findings from a systematic review and meta-analysis presented at the...
Doublet in Low-Risk Gestational Trophoblastic Tumors
In a French phase I/II trial (TROPHAMET) reported in JAMA Oncology, You et al found that first-line avelumab plus methotrexate was associated with high efficacy in patients with low-risk gestational trophoblastic tumors.
Study Details
In the multicenter study, 27 patients with low-risk...
Ultra–High-Risk LBCL: Does High-Dose Methotrexate Reduce Rates of CNS Relapse?
In an analysis reported in the Journal of Clinical Oncology, Wilson et al found that prophylactic high-dose methotrexate does not provide significant benefit in reducing central nervous system (CNS) relapse in patients with ultra–high-risk large B-cell lymphoma (LBCL).
Study Details
The analysis...
FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved the antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) for two indications in adults with triple-negative breast cancer (TNBC).
The first indication, supported by data from ASCENT-03, is for sacituzumab govitecan as...
Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer
Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer derived from screening mammograms evolve over time and differ between women who develop cancer and those who do not, opening the door to a new era of dynamic breast cancer risk assessment. The new...
Multi-Cancer Early Detection Test Evaluated in Real-World Asian Cohort
A large real-world study conducted across six Asian countries suggests that a blood-based multi-cancer early detection (MCED) test may accurately identify multiple cancer types in routine clinical practice, including cancers for which no standard screening programs currently exist. The research was ...
Subgroup Analysis of Inavolisib Regimen in Asian Patients With Advanced Breast Cancer
Treatment with the PI3K inhibitor inavolisib in combination with palbociclib and fulvestrant produced substantial clinical benefits in Asian patients with PIK3CA-mutated, hormone receptor–positive (HR-positive), HER2-negative, endocrine-resistant advanced breast cancer, according to a subgroup...
Chinese Study of HER2-Targeted Combination in Neoadjuvant Therapy for Locally Advanced Breast Cancer
A HER2-targeted regimen produced high pathologic complete response rates before surgery in patients with locally advanced HER2-positive breast cancer, according to results from a single-arm phase II neoadjuvant trial conducted in China. The research was highlighted in a media briefing ahead of the...
Impact of Early Palliative Care on Quality of Life in Patients With Breast Cancer in India
Early integration of palliative, or supportive, care at the time of breast cancer diagnosis improved quality of life more than on-demand palliative care in a randomized trial of patients in India. The research was highlighted in a media briefing ahead of the 2026 ASCO Breakthrough Meeting, taking...
Advanced Breast Cancer: Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor
In an interim analysis of a Chinese phase III trial (FCN-437c-III201) reported in JAMA Oncology, Yuan et al found that the addition of the novel CDK4/6 inhibitor fovinaciclib to aromatase inhibitor therapy was associated with significant improvement in progression-free survival in the first-line...
Educational Gaps Found in Cardio-Oncology Training
Educational gaps in cardio-oncology training have been identified in the results of an international survey presented at the European Society of Cardiology (ESC) Congress 2026.
“The survey identified profound gaps in cardio-oncology education during medical school and residency and in structured...
Talquetamab Combinations in Relapsed or Refractory Myeloma
In an interim analysis of a phase III trial (MonumenTAL-3) reported in The New England Journal of Medicine, Mina et al found that the combinations of talquetamab with daratumumab/pomalidomide (Tal-DP) and talquetamab plus daratumumab (Tal-D) improved progression-free survival vs...
Wearable Devices May Help Detect CRS Earlier in Patients With Myeloma Receiving CAR T-Cell Therapy
Researchers have found that wearable devices may help clinicians detect cytokine-release syndrome—a common and potentially serious side effect of chimeric antigen receptor (CAR) T-cell therapy—hours earlier than standard hospital monitoring in patients with multiple myeloma.
The findings,...
New Section Chief of Medical Oncology and Hematology and Deputy Director for Clinical Affairs for Yale Cancer Center and Smilow Cancer Hospital Named
Ian E. Krop, MD, PhD, has been named as Section Chief of Medical Oncology and Hematology and Deputy Director for Clinical Affairs for Yale Cancer Center and Smilow Cancer Hospital. Dr. Krop is an international leader in breast cancer care and clinical investigation. He joined Yale in 2022 and is a...
Aumolertinib Plus Chemotherapy in EGFR-Mutated Advanced NSCLC
In a Chinese phase III trial (AENEAS2) reported in The Lancet Oncology, Li et al found that the combination of aumolertinib with chemotherapy significantly improved progression-free survival vs aumolertinib alone in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC).
Study...
Low-Dose Tamoxifen in Noninvasive Breast Neoplasia
In a long-term individual patient-level pooled analysis reported in the Journal of Clinical Oncology, Gandini et al found that low-dose tamoxifen was associated with good outcomes in patients with noninvasive breast neoplasia.
Study Details
The study used individual patient data from three...
AI-Assisted Tumor Volume Response Criteria Outperform Physician Assessments and RECIST Criteria in Pleural Mesothelioma
Researchers have developed and validated an artificial intelligence (AI)‒assisted volumetric response criteria for assessing response in pleural mesothelioma. The AI-backed criteria outperformed both humans and standard international Response Evaluation Criteria in Solid Tumors (RECIST) criteria,...
Metastatic Colorectal Cancer: GUCY2C-Targeted CAR T-Cell Therapy
In a Chinese phase I dose-escalation and dose-expansion study reported in the Journal of Clinical Oncology, Qi et al found that guanylyl cyclase 2C (GUCY2C)-targeted chimeric antigen receptor (CAR) T-cell therapy had an “acceptable” safety profile and was active in patients with previously treated...
Ga-68–PSMA-11 PET/CT in Diagnosis of Prostate Cancer
In an Australian phase III noninferiority trial reported in The Lancet Oncology, Buteau et al found that use of gallium-68–labeled PSMA-11 (Ga-68–PSMA-11) positron-emission tomography/computed tomography (PET/CT) could improve the pathway of diagnosis of prostate cancer in men with clinical...
Addition of Mezigdomide to Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma
In an interim analysis of a phase III trial (SUCCESOR-2) reported in The Lancet, Dimopoulos et al found that the addition of the cereblon E3 ligase modulator mezigdomide to carfilzomib/dexamethasone significantly improved progression-free survival in previously treated patients with relapsed or...
AGA Recommends Colonoscopy Over Alternative Colorectal Cancer Screening Methods
The American Gastroenterological Association (AGA) recently reported that among expanding options for colorectal cancer screening, colonoscopy remains the AGA's top recommendation.
In a business announcement, the organization noted that new screening guidance has alerted patients and primary care...
Overall Survival With EBRT in Hepatocellular Carcinoma
In an individual patient analysis reported in the Journal of Clinical Oncology, Moon et al found that treatment of early-stage hepatocellular carcinoma (HCC) with external-beam radiation therapy (EBRT) was associated with survival outcomes comparable to other treatment modalities such as surgical...
HCC: TACE Plus STRIDE With or Without Lenvatinib
Results from the phase III EMERALD-3 study found that combining the standard treatment of transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab, regular interval durvalumab) regimen, with or without the targeted therapy lenvatinib, can slow the cancer’s...
St. Jude Redesignation Marks Collaboration With WHO Toward Improved Pediatric Cancer Outcomes Globally
St. Jude Children's Research Hospital has announced that they have been redesignated as a World Health Organization (WHO) Collaborating Centre for Childhood Cancer. The new designation recognizes the work of St. Jude to support WHO in integrating childhood cancer into national cancer control plans; ...
FDA Warns of Ongoing Breast Biopsy Needle Shortage
The U.S. Food and Drug Administration (FDA) issued notice of supply chain interruptions for stereotactic breast biopsy needles due to recent supplier issues. Disruption in biopsy needle manufacturing is expected to impact patient care and could require adjustments for the management of patients...
New ACSM Expert Consensus Statement: Exercise in Children and Adolescents With Cancer
In children and adolescents undergoing cancer treatment, exercise can be performed safely during and after therapy when appropriately supervised and individualized; further, appropriately prescribed exercise should be included as part of supportive cancer care, according to a new American College...
Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab
Patients with multiple myeloma who received a new immunotherapy combination had significantly longer progression-free survival and showed early signs of improved overall survival, according to findings from the phase III MonumenTAL-3 trial.
Peter M. Voorhees, MD, Professor of Medicine at Wake...
Neoadjuvant Sacituzumab Govitecan in MIBC
In an Italian phase II trial (SURE-01) reported in the Journal of Clinical Oncology, Necchi et al found that neoadjuvant sacituzumab govitecan was active in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for or elected not to receive neoadjuvant chemotherapy.
Study Details
...
Thyroid Cancer: Reproductive Lifespan, Hormone Therapy Potentially Linked to Incidence
Longer exposure to hormone replacement therapy and longer reproductive lifespan showed potential associations with increased thyroid cancer risk in women, according to findings presented at ENDO 2026 (Abstract ORF12-08).
“These results show how common life events in women, such as the timing of...
MIBC: Intravesical Recombinant BCG and Chemoimmunotherapy
In a Swiss phase II trial (SAKK 06/19) reported at the 2026 ASCO Annual Meeting (Abstract 4503) and published in the Journal of Clinical Oncology, Cathomas et al found that the addition of intravesical recombinant bacillus Calmette-Guérin (rBCG) to perioperative chemoimmunotherapy was associated...
Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC
New findings from the phase III HARMONi-6 trial presented at the 2026 ASCO Annual Meeting showed that the investigational bispecific antibody ivonescimab combined with chemotherapy significantly improved overall survival compared with tislelizumab plus chemotherapy in patients with advanced...
Lu-177 Dotatate in Metastatic Pancreatic Neuroendocrine Tumors
In a French phase II noncomparative trial (OCLURANDOM) reported in The Lancet Oncology, Baudin et al found that lutetium Lu-177 dotatate (Lu-177 dotatate) produced numerically better progression-free survival results than those achieved with sunitinib when used as an internal control in patients...
Long-Term Outcomes of Adjuvant Hypofractionated Radiotherapy for Breast Cancer
As reported in The Lancet Oncology by Brunt et al, long-term follow-up of the UK phase III FAST-Forward trial has shown that a 1-week adjuvant radiotherapy schedule was associated with good outcomes at 10 years in patients with breast cancer.
Study Details
In the multicenter, open-label,...
Machine Learning Model May Improve Accuracy of Liquid Biopsy Results
A machine learning model developed by researchers at the Johns Hopkins Kimmel Cancer Center filters out the biological noise in liquid biopsy samples, helping clinicians better match therapies to their patients’ tumors. These findings were published by Canzoniero et al in Clinical Cancer Research.
...
TP53 Mutation Acquisition Timing Influences Prognosis in MPNs, Study Finds
The timing of TP53 mutation acquisition carries important prognostic implications for patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes/MPN overlap disorders. Later emergence of the mutation is associated with significantly worse survival outcomes, according to a...
Novel Gene Therapy–Radiotherapy Combination in Localized Prostate Cancer
As reported in The Lancet Oncology by DeWeese et al, the phase III PrTK03 trial has shown improved disease-free survival with the addition of aglatimagene besadenovec (aglatimagene) to valacyclovir in patients receiving standard radiation therapy for localized prostate cancer. Aglatimagene is an...
Can AI Provide an ‘Early Alert’ for Breast Cancer Before Diagnosis?
Three commercially available radiology artificial intelligence (AI) systems have shown the potential to flag early signs of breast cancer up to 6 years before a diagnosis, according to a Swedish study published by Hickman et al in Radiology.
In a retrospective study, researchers tested three...
Urologic Surgeon Sworn in as AMA President
Willie Underwood III, MD, MSc, MPH, a urologic surgeon based in Buffalo, New York, was sworn on June 9 as the 181st President of the American Medical Association (AMA).
Assuming the presidency at a pivotal moment for American health care, Dr. Underwood pledged during his inaugural address at AMA...
Head and Neck Cancer: HPV-DeepSeek May Identify Earlier Signs of Postoperative Recurrence
Researchers clinically validated a sensitive blood test as a whole-genome sequencing assay for detecting circulating tumor human papillomavirus (HPV) DNA in patients with HPV-associated head and neck cancer after surgery to search for residual disease as a sign of potential recurrence, according to ...
FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive Muscle-Invasive Bladder Cancer
On May 15, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhbitor atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant therapies for adults with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA...
Perioperative Serplulimab in PD-L1–Positive Gastric Cancer
In a Chinese phase III study (ASTRUM-006) reported in The Lancet, Shen et al found that neoadjuvant serplulimab plus S-1/oxaliplatin (SOX) followed by adjuvant serplulimab improved event-free survival vs neoadjuvant and adjuvant SOX in patients with PD-L1–positive, resectable gastric or...
New Research Links Low Alcohol Consumption to Elevated Health Risks
Researchers reported there was no protective net effect of any level of alcohol consumption on health observed in a new study published by George et al in the Journal of Studies on Alcohol and Drugs. Further, researchers reported that low levels of alcohol use may be associated with elevated health ...
Digital Tool May Improve Patient Engagement in Oncology Clinical Trials
In a step forward for patient-centered cancer research, a new pilot project reveals that 84% of participants had a positive experience using a newly developed online tool created by the Alliance for Clinical Trials in Oncology called the Participant Engagement Portal (PEP). Alliance created PEP to...
GLP-1 RAs May Reduce Risk of Obesity-Related Cancers
Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with a 41% lower risk of developing obesity-associated cancers in the short term for obese, nondiabetic patients, according to findings from an observational study published in Annals of Oncology.
“Our study found that...
Teclistamab in Previously Treated Multiple Myeloma
As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Touzeau et al, an interim analysis of the phase III MajesTEC-9 trial has shown improved progression-free survival with teclistamab vs investigator's choice of pomalidomide, bortezomib, and dexamethasone (PVd)...
Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer
As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Agarwal et al, the phase III TALAPRO-3 trial has shown improved imaging-based progression-free survival with the addition of talazoparib to enzalutamide in patients receiving androgen-deprivation therapy for...
Sunvozertinib in NSCLC With EGFR Exon 20 Insertion Mutations
As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Zhou et al, the phase III WU-KONG28 trial has shown that first-line sunvozertinib improved progression-free survival vs chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC)...
FDA Approves Durvalumab Plus BCG for High-Risk NMIBC
On May 28, 2026, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC).
Efficacy and Safety
Which Genes Contribute to Early-Onset Breast Cancer in Black Women?
Black women experience disproportionately elevated risks of developing and dying from early-onset breast cancer. New research published by Beasley et al in Cancer reveals the genes that are most likely to be mutated to contribute to these increased risks.
In the study of 686 Black women diagnosed...
AML: All-Oral Regimen Safe and Eases Treatment Administration Burden
An all-oral treatment regimen led to complete responses in almost half of all patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, according to findings from the phase I/II ASCERTAIN V trial published in The New England Journal of Medicine.
...
Study Identifies Serious Infection Risks Linked to Antibody-Drug Conjugates
A major real-world study has found serious blood-related side effects associated with antibody-drug conjugates (ADCs), an increasingly important class of targeted cancer therapies. Over the years, many novel ADC therapies have been approved for treating various types of cancers.
The study,...
SCLC With Brain-Only Progression: Original or Substitute Systemic Therapy With or Without Brain Radiotherapy
In a Chinese retrospective cohort study reported in the Journal of Clinical Oncology, Lu et al found that adding brain radiotherapy to continued original systemic therapy produced better outcomes compared to brain radiotherapy and substitution of systemic therapy or substitution of systemic therapy ...
Five-Year Survival Analysis: Neoadjuvant Trastuzumab/Pertuzumab Plus Endocrine Therapy or Chemotherapy in HR-Positive/HER2-Positive Breast Cancer
In an analysis of the German phase II WSG TP-II trial reported in the Journal of Clinical Oncology, Gluz et al found that neoadjuvant trastuzumab/pertuzumab with endocrine therapy (ET) or paclitaxel were both associated with high rates of 5-year overall survival in patients with hormone receptor...
Annual Galleri Screening Reduced Stage IV Cancer Diagnoses but Missed Primary Endpoint in First Randomized MCED Trial
Results from the first randomized controlled trial evaluating a multicancer early detection (MCED) blood test suggest that annual screening with the Galleri test may alter the stage at which cancers are diagnosed, reducing the burden of stage IV cancers. However, the study did not achieve its...
GLP-1 RAs May Be Associated With Lower Breast Cancer Incidence
Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may lower the risk of breast cancer incidence, according to findings from a retrospective analysis presented at the 2026 ASCO Annual Meeting (Abstract 10506). The findings were also published in JCO Oncology Practice.
“While our...
American Cancer Society Updates Colorectal Cancer Screening Guideline
The American Cancer Society (ACS) recently released updated guidelines for colorectal cancer screening. The new recommendations reaffirm that average-risk adults should begin colorectal cancer screening at age 45 years and continue through age 75 years for those with a life expectancy greater than...
Long-Term Follow-Up of Three First-Line Regimens in Mantle Cell Lymphoma
In an analysis reported in The Lancet, Dreyling et al provided long-term findings with three first-line regimens in the phase III TRIANGLE trial among patients aged 18 to 65 years with mantle cell lymphoma.
Study Details
In the international (13 European countries and Israel) open-label trial,...
Does Tissue TMB Outperform Blood-Based Testing for Predicting Immunotherapy Response?
A new study from Cleveland Clinic researchers confirms that tissue-derived tumor mutation burden (TMB) remains the more reliable predictor of immunotherapy response in patients with solid tumors. Results were presented at the 2026 ASCO Annual Meeting (Abstract 2580).
“This is really a cautionary...
Online Patient Resources About AI and Cancer Found Lacking
Online resources for patients and the general public focused on artificial intelligence (AI) and its uses in cancer research and cancer care were found lacking in a cross-sectional analysis presented at the 2026 ASCO Annual Meeting (Abstract 9000). The study highlighted that the existing webpages...
Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma
The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared with pembrolizumab alone in patients with high-risk resected melanoma, according to 5-year results...
Phase III Trial Shows Noninferiority for Test-Guided Chemotherapy Decisions in ER-Positive/HER2-Negative Early Breast Cancer
Individuals with estrogen receptor–positive, HER2-negative, high-risk early breast cancer and low Prosigna (PAM50) risk of recurrence (ROR) scores of 60 or less were able to safely skip chemotherapy, according to findings from a randomized, noninferiority phase III trial presented at the 2026 ASCO...
Friends of Cancer Research Names Richard Pazdur, MD, to Board of Directors
Friends of Cancer Research announced the election of Richard Pazdur, MD, to its Board of Directors. Dr. Pazdur spent 26 years at the U.S. Food and Drug Administration, where he served as the founding director of the Oncology Center of Excellence and played a leading role in shaping the regulatory...
Cochrane Review Finds Current Breast Cancer Risk Models Have Limited Accuracy in Women With a Family History of Disease
A comprehensive Cochrane review presented at the 2026 ASCO Annual Meeting suggests that commonly used breast cancer risk prediction models provide only modest accuracy in identifying which women with a family history of breast cancer will ultimately develop the disease (Abstract 10545). Although...
